Click here to take the survey

The trend to the early use of higher-efficacy disease-modifying therapies (DMT) in the management of MS was put on pause during the pandemic due to concerns about the effects of these agents on the immune response to SARS-CoV-2 and, latterly, to COVID-19 vaccination. However, as the pandemic dragged on, it became impractical to interrupt or delay treatment, and current DMT recommendations now emphasize that the risks of undertreated MS outweigh the possible risks of COVID, especially in a younger population. Read More

Part 2

Part 1:
The following summarizes some of the highlights from the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum, held February 25-27, 2021. Read More